Top

Published in:

18-09-2021 | Leflunomide | Pharmacoeconomics

The temporal association between hospital admissions, biological therapy usage and direct health care costs in rheumatoid arthritis patients

Authors: Khalid Almutairi, Johannes Nossent, David B. Preen, Helen Keen, Charles Inderjeeth

Published in: Rheumatology International | Issue 11/2022

Abstract

The Australian Pharmaceutical Benefits Scheme (PBS) has subsidised biological therapy since 2003. We investigated the association between biological therapy for RA hospitalisation rates and health-care costs.

Hospital admissions for RA patients between 1995 and 2014 were identified in the Western Australia (WA) Hospital Morbidity Data Collection (ICD codes 714 and M05.00–M06.99). State-specific dispensing data for conventional and biological therapies for RA was obtained from Statistics Australia and expressed as defined daily doses/1000 population/day (DDD) using WA population census. Principal component analysis (PCA) was applied to determine the relationship between DMARDs use and hospital admission rates.

A total of 17,125 patients had 50,353 admissions with a diagnostic code for RA. Between 1995 and 2002, the number of RA admissions fell from 7.9 to 2.6/1000 admissions, while conventional therapy use rose from 1.45 to 1.84 DDD. Between 2003 and 2014, RA admissions decreased further to 1.9/1000 hospital admissions, while conventional therapy use increased to 2.19 DDD and biological therapy from 0.01 to 1.0 DDD. In PCA, conventional and biological therapies use had an inverse relationship with hospital admission rates. Annual costs of biological therapy utilisation was 22.5 million in 2003–2014, while the annual cost saving of RA hospital admissions was 9.2 million.

The increased use of conventional therapy use for RA has coincided with a significant decline in hospital admissions for RA patients in WA, while a more modest further decline followed biological therapy introduction. Biological therapy was not as cost-effective as conventional in relation to RA hospital admissions costs.

Available only for authorised users

Guo Q, Wang Y, Xu D, Nossent J, Pavlos NJ, Xu J (2018) Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res 6(15):1–14. https://doi.org/10.1038/s41413-018-0016-9 CrossRef

Alam J, Jantan I, Bukhari SNA (2017) Rheumatoid arthritis: recent advances on its etiology, role of cytokines and pharmacotherapy. Biomed Pharmacother 92:615–633. https://doi.org/10.1016/j.biopha.2017.05.055 CrossRefPubMed

Smolen JS, Landewé RB, Bijlsma JW, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, Van Vollenhoven RF, De Wit M (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79(6):685–699. https://doi.org/10.1136/annrheumdis-2019-216655 CrossRefPubMed

Wilske KR, Healey LA (1990) Challenging the therapeutic pyramid: a new look at treatment strategies for rheumatoid arthritis. J Rheumatol Suppl 25:4–7 PubMed

Combe B (2007) Early rheumatoid arthritis: strategies for prevention and management. Best Pract Res Clin Rheumatol 21:27–42. https://doi.org/10.1016/j.berh.2006.08.011 CrossRefPubMed

Hetland ML, Haavardsholm EA, Rudin A, Nordström D, Nurmohamed M, Gudbjornsson B, Lampa J, Hørslev-Petersen K, Uhlig T, Grondal G (2020) Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial. BMJ 371:m4328. https://doi.org/10.1136/bmj.m4328 CrossRefPubMedPubMedCentral

Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, Singh A, Pedersen RD, Koenig AS, Freundlich B (2008) Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372:375–382. https://doi.org/10.1016/s0140-6736(08)61000-4 CrossRefPubMed

Klarenbeek NB, Güler-Yüksel M, van der Kooij SM, Han KH, Ronday HK, Kerstens PJ, Seys PE, Huizinga TW, Dijkmans BA, Allaart CF (2011) The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis 70:1039–1046. https://doi.org/10.1136/ard.2010.141234 CrossRefPubMed

Singh JA, Hossain A, Ghogomu ET, Kotb A, Christensen R, Mudano AS, Maxwell LJ, Shah NP, Tugwell P, Wells GA (2016) Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. Cochrane Database Syst Rev 5:CD012183. https://doi.org/10.1002/14651858.CD012183 CrossRef

10.

Verstappen SM, Jacobs JW, Kruize AA, Ehrlich JC, van Albada-Kuipers GA, Verkleij H, Buskens E, Bijlsma JW (2007) Trends in economic consequences of rheumatoid arthritis over two subsequent years. Rheumatology (Oxford) 46:968–974. https://doi.org/10.1093/rheumatology/kem018 CrossRef

11.

Holroyd CR, Seth R, Bukhari M, Malaviya A, Holmes C, Curtis E, Chan C, Yusuf MA, Litwic A, Smolen S, Topliffe J, Bennett S, Humphreys J, Green M, Ledingham J (2019) The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis-executive summary. Rheumatology (Oxford) 58:220–226. https://doi.org/10.1093/rheumatology/key207 CrossRef

12.

Joensuu JT, Aaltonen KJ, Aronen P, Sokka T, Puolakka K, Tuompo R, Korpela M, Vasala M, Ilva K, Nordström D, Blom M (2016) Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study. Rheumatology (Oxford) 55:1803–1811. https://doi.org/10.1093/rheumatology/kew264 CrossRef

13.

Medicare Australia (2020) Pharmaceutical benefits schedule item reports. https://www.servicesaustralia.gov.au/organisations/about-us/statistical-information-and-data/medicare-statistics#a1 Accessed 24 July 2021

14.

Nossent JC, Raymond W, Keen H, Preen DB, Inderjeeth CA (2020) Infection rates before and after diagnosis of IgA vasculitis in childhood: a population-wide study using non-exposed matched controls. J Rheumatol 47:424–430 CrossRef

15.

Ognjenovic M, Raymond W, Inderjeeth C, Keen H, Preen D, Nossent J (2020) The risk and consequences of vertebral fracture in patients with ankylosing spondylitis: a population-based data linkage study. J Rheumatol 47(11):1629–1636. https://doi.org/10.3899/jrheum.190675 CrossRefPubMed

16.

Lacaille D, Anis AH, Guh DP, Esdaile JM (2005) Gaps in care for rheumatoid arthritis: a population study. Arthritis Rheum 53:241–248. https://doi.org/10.1002/art.21077 CrossRefPubMed

17.

Almutairi K, Inderjeeth C, Preen DB, Keen H, Rogers K, Nossent J (2021) The accuracy of administrative health data for identifying patients with rheumatoid arthritis: a retrospective validation study using medical records in Western Australia. Rheumatol Int 41:741–750. https://doi.org/10.1007/s00296-021-04811-9 CrossRefPubMed

18.

Waters A-M, Armstrong T, Senes-Ferrari S (1998) Medical care of cardiovascular disease in Australia. AIHW. https://www.aihw.gov.au/reports/heart-stroke-vascular-diseases/medical-care-cardiovascular-disease-australia/contents/summary. Accessed 24 July 2021

19.

Australian Bureau of statistics (2014) Estimated resident population by age and sex. https://stat.data.abs.gov.au. Accessed 24 July 2021

20.

Kelman CW, Bass AJ, Holman CD (2002) Research use of linked health data—a best practice protocol. Aust N Z J Public Health 26:251–255. https://doi.org/10.1111/j.1467-842x.2002.tb00682.x CrossRefPubMed

21.

Li JH, Morlet N, Semmens J, Gavin A, Ng J, Team E (2003) Coding accuracy for endophthalmitis diagnosis and cataract procedures in western Australia—The Endophthalmitis Population Study of Western Australia (EPSWA): second report. Ophthalmic Epidemiol 10:133–145. https://doi.org/10.1076/opep.10.2.133.13898 CrossRefPubMed

22.

Preen DB, Holman CAJ, Lawrence DM, Baynham NJ, Semmens JB (2004) Hospital chart review provided more accurate comorbidity information than data from a general practitioner survey or an administrative database. J Clin Epidemiol 57:1295–1304. https://doi.org/10.1016/j.jclinepi.2004.03.016 CrossRefPubMed

23.

Valinsky LJ, Hockey RL, Hobbs MST, Fletcher DR, Pikora TJ, Parsons RW, Tan P (1999) Finding bile duct injuries using record linkage: a validated study of complications following cholecystectomy. J Clin Epidemiol 52:893–901. https://doi.org/10.1016/s0895-4356(99)00043-8 CrossRefPubMed

24.

Clark A, Morlet N, Ng JQ, Preen DB, Semmens JB (2011) Whole Population trends in complications of cataract surgery over 22 years in Western Australia. Ophthalmology 118:1055–1061. https://doi.org/10.1016/j.ophtha.2010.11.001 CrossRefPubMed

25.

Australian Institute of Health and Welfare (2014) Health-care expenditure on arthritis and other musculoskeletal conditions 2008–09. https://www.aihw.gov.au/reports/health-welfare-expenditure/health-care-expenditure-2008-09/contents/table-of-contents. Accessed 24 July 2021

26.

James G, Witten D, Hastie T, Tibshirani R (2013) An introduction to statistical learning with applications in R. Springer, New York. https://doi.org/10.1007/978-1-4614-7138-7 CrossRef

27.

Gwelo AS (2019) Principal components to overcome multicollinearity problem. Oradea J Bus Econ 4:79–91. https://doi.org/10.47535/1991ojbe062

28.

Commonwealth Department of Health and Family Services (1996) The National Public Health Partnership-Commonwealth and State and Territory co-operation. Health Promot J Austr 6(3):60–63. https://doi.org/10.3316/informit.460949110789506 CrossRef

29.

National Public Health Partnership (2001) Preventing chronic disease: a strategic framework. https://commed.vcu.edu/Chronic_Disease/2015/NPHPProject.pdf . Accessed 24 July 2021

30.

Van der Horst-Bruinsma I, Speyer I, Visser H, Breedveld F, Hazes J (1998) Diagnosis and course of early-onset arthritis: results of a special early arthritis clinic compared to routine patient care. Br J Rheumatol 37:1084–1088. https://doi.org/10.1093/rheumatology/37.10.1084 CrossRefPubMed

31.

Irvine S, Munro R, Porter D (1999) Early referral, diagnosis, and treatment of rheumatoid arthritis: evidence for changing medical practice. Ann Rheum Dis 58:510–513. https://doi.org/10.1136/ard.58.8.510 CrossRefPubMedPubMedCentral

32.

Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, van Zeben D, Dijkmans BA, Peeters AJ, Jacobs P (1997) Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350:309–318. https://doi.org/10.1016/s0140-6736(97)01300-7 CrossRefPubMed

33.

Keyszer G, Keysser C, Keysser M (1999) Efficacy and safety of a combination therapy of methotrexate, chloroquine and cyclophosphamide in patients with refractory rheumatoid arthritis: results of an observational study with matched-pair analysis. Clin Rheumatol 18:145–151. https://doi.org/10.1007/s100670050073 CrossRefPubMed

34.

Collings S, Highton J (2002) Changing patterns of hospital admissions for patients with rheumatic diseases. N Z Med J 115:131–132 PubMed

35.

Guidelines for the management of rheumatoid arthritis (1996) American College of Rheumatology ad hoc committee on clinical guidelines. Arthritis Rheum 39:713–722. https://doi.org/10.1002/art.1780390502 CrossRef

36.

Gil-Conesa M, Del-Moral-Luque JA, Gil-Prieto R, Gil-de-Miguel Á, Mazzuccheli-Esteban R, Rodríguez-Caravaca G (2020) Hospitalization burden and comorbidities of patients with rheumatoid arthritis in Spain during the period 2002–2017. BMC Health Serv Res 20:1–8. https://doi.org/10.1186/s12913-020-05243-0 CrossRef

37.

Rai SK, Avina-Zubieta JA, McCormick N, De Vera MA, Lacaille D, Sayre EC, Choi HK (2017) Trends in gout and rheumatoid arthritis hospitalizations in Canada From 2000 to 2011. Arthritis Care Res (Hoboken) 69:758–762. https://doi.org/10.1002/acr.23012 CrossRef

38.

Australian Institute of Health and Welfare (2011) The use of disease-modifying anti-rheumatic drugs for the management of rheumatoid arthritis. AIHW. https://www.aihw.gov.au/reports/chronic-musculoskeletal-conditions/anti-rheumatic-drugs-rheumatoid-arthritis/contents/table-of-contents. Accessed 24 July 2021

39.

Cordtz RL, Hawley S, Prieto-Alhambra D, Højgaard P, Zobbe K, Overgaard S, Odgaard A, Kristensen LE, Dreyer L (2018) Incidence of hip and knee replacement in patients with rheumatoid arthritis following the introduction of biological DMARDs: an interrupted time-series analysis using nationwide Danish healthcare registers. Ann Rheum Dis 77:684–689. https://doi.org/10.1136/annrheumdis-2017-212424 CrossRefPubMed

40.

Hawley S, Cordtz R, Dreyer L, Edwards CJ, Arden NK, Delmestri A, Silman A, Cooper C, Judge A, Prieto-Alhambra D (2018) Association between NICE guidance on biologic therapies with rates of hip and knee replacement among rheumatoid arthritis patients in England and Wales: an interrupted time-series analysis. Semin Arthritis Rheum 47:605–610. https://doi.org/10.1016/j.semarthrit.2017.09.006 CrossRefPubMed

41.

Ichinose K, Shimizu T, Umeda M, Fukui S, Nishino A, Koga T, Kawashiri S-y, Iwamoto N, Tamai M, Nakamura H (2018) Frequency of hospitalized infections is reduced in rheumatoid arthritis patients who received biological and targeted synthetic disease-modifying antirheumatic drugs after 2010. J Immunol Res 2018:6259010. https://doi.org/10.1155/2018/6259010 CrossRefPubMedPubMedCentral

42.

Silvagni E, Bortoluzzi A, Carrara G, Zanetti A, Govoni M, Scirè CA (2018) Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases. BMJ Open 8:e021447. https://doi.org/10.1136/bmjopen-2017-021447 CrossRefPubMedPubMedCentral

43.

Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, Trudeau J, Bombardier C, Carmona L, van der Heijde D, Bijlsma JW, Boumpas DT, Canhao H, Edwards CJ, Hamuryudan V, Kvien TK, Leeb BF, Martín-Mola EM, Mielants H, Müller-Ladner U, Murphy G, Østergaard M, Pereira IA, Ramos-Remus C, Valentini G, Zochling J, Dougados M (2009) Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 68:1086–1093. https://doi.org/10.1136/ard.2008.094474 CrossRefPubMed

44.

Betts KA, Griffith J, Ganguli A, Li N, Douglas K, Wu EQ (2016) Economic burden and treatment patterns of cycling between conventional synthetic disease-modifying antirheumatic drugs among biologic-treated patients with rheumatoid arthritis. Clin Ther 38:1205–1216. https://doi.org/10.1016/j.clinthera.2016.03.013 CrossRefPubMed

45.

Birnbaum HG, Pike C, Banerjee R, Waldman T, Cifaldi M (2012) Changes in utilization and costs for patients with rheumatoid arthritis, 1997 to 2006. Pharmacoeconomics 30:323–336. https://doi.org/10.2165/11589470-000000000-00000 CrossRefPubMed

46.

Chen DY, Yu F, Tuan LW, Tang CH (2019) Comparison of healthcare utilization and costs between RA patients receiving biological and conventional synthetic DMARDs: a nationwide population-based cohort study in Taiwan. Front Pharmacol 10:1214. https://doi.org/10.3389/fphar.2019.01214 CrossRefPubMedPubMedCentral

47.

Solomon DH, Curtis JR, Saag KG, Lii J, Chen L, Harrold LR, Herrinton LJ, Graham DJ, Kowal MK, Kuriya B, Liu L, Griffin MR, Lewis JD, Rassen JA (2013) Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs. Am J Med 126:730.e739-730.e717. https://doi.org/10.1016/j.amjmed.2013.02.016 CrossRef

48.

Birkner B, Rech J, Stargardt T (2020) Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. PLoS ONE 15:e0226754. https://doi.org/10.1371/journal.pone.0226754 CrossRefPubMedPubMedCentral

49.

Grijalva CG, Kaltenbach L, Arbogast PG, Mitchel EF Jr, Griffin MR (2010) Adherence to disease-modifying antirheumatic drugs and the effects of exposure misclassification on the risk of hospital admission. Arthritis Care Res (Hoboken) 62:730–734. https://doi.org/10.1002/acr.20087 CrossRef

50.

Mellish L, Karanges EA, Litchfield MJ, Schaffer AL, Blanch B, Daniels BJ, Segrave A, Pearson S-A (2015) The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers. BMC Res Notes 8:1–13. https://doi.org/10.1186/s13104-015-1616-8 CrossRef

Title: The temporal association between hospital admissions, biological therapy usage and direct health care costs in rheumatoid arthritis patients
Authors: Khalid Almutairi
Johannes Nossent
David B. Preen
Helen Keen
Charles Inderjeeth
Publication date: 18-09-2021
Publisher: Springer Berlin Heidelberg
Keywords: Leflunomide
Disease Modifying Anti-Rheumatic Drug
Methotrexate
Care
Methotrexate
Rheumatoid Arthritis
Sodium Aurothiomalate
Published in: Rheumatology International / Issue 11/2022
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-021-04985-2

Webinar | 08-11-2023 | 18:00 (CET)

Keynote Webinar | Spotlight on Diet and Diabetes

Watch now

An expert-led symposium exploring the prevention and management of type 2 diabetes through dietary interventions. Highlights include discussion of the recent EASD guidelines, therapeutic diets, food types and processing, plus psychological factors that influence patient success, and the drivers of healthy eating and diabetes control.

Prof. Mike Lean

Prof. Falko Sniehotta

Keynote Webinar | Spotlight on Diet and Diabetes

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2022

Tumor necrosis factor inhibitor (TNFi) persistence and reasons for discontinuation in a predominantly male cohort with axial spondyloarthritis

Optical imaging compared to clinical examination in 484 rheumatoid arthritis patients: the Leeuwarden Handscan Registry

The reliability, validity, and responsiveness of Cognitive Exercise Therapy Approach: Biopsychosocial Questionnaire for patients with psoriatic arthritis

The association of breathing pattern with exercise tolerance and perceived fatigue in women with systemic lupus erythematosus: an exploratory case–control study

Nanotechnology applications in rheumatology

Multi-targeted therapy for refractory eosinophilic granulomatosis with polyangiitis characterized by intracerebral hemorrhage and cardiomyopathy: a case-based review

Keynote Webinar | Spotlight on Diet and Diabetes